Rachael E. Wilson
YOU?
Author Swipe
View article: CSF total tau as a proxy of synaptic degeneration
CSF total tau as a proxy of synaptic degeneration Open
Cerebrospinal fluid (CSF) total tau (t-tau) is considered a biomarker of neuronal degeneration alongside brain atrophy and fluid neurofilament light chain protein (NfL) in biomarker models of Alzheimer’s disease (AD). However, previous stu…
View article: Lifestyle, genetic risk, plasma pTau217, and incident cognitive impairment in WRAP
Lifestyle, genetic risk, plasma pTau217, and incident cognitive impairment in WRAP Open
INTRODUCTION Whether lifestyle‐based dementia risk in midlife impacts risk of incident cognitive impairment (ICI) in the presence of apolipoprotein E ( APOE ) ε4 allele or plasma pTau217 remains unknown. METHODS In initially cognitively un…
View article: Preclinical dementia rating scores are associated with plasma phosphorylated tau‐217
Preclinical dementia rating scores are associated with plasma phosphorylated tau‐217 Open
INTRODUCTION Simple screening tools are critical for assessing Alzheimer's disease (AD)‐related pre‐dementia changes. This study investigated longitudinal scores from the Quick Dementia Rating System (QDRS), a brief study partner‐reported …
View article: Synaptic markers are associated with cognitive decline after accounting for amyloid burden among an at-risk Alzheimer’s disease cohort
Synaptic markers are associated with cognitive decline after accounting for amyloid burden among an at-risk Alzheimer’s disease cohort Open
View article: Use of preclinical Alzheimer’s disease trajectories for clinical trial design
Use of preclinical Alzheimer’s disease trajectories for clinical trial design Open
INTRODUCTION This study uses longitudinal amyloid biomarker and cognitive data to generate sample size estimates for two-armed, pre-clinical amyloid clearance clinical trials. METHODS PET PiB DVR ranges defined three amyloid groups (positi…
View article: Misfolded α‐synuclein co‐occurrence with Alzheimer's disease proteinopathy
Misfolded α‐synuclein co‐occurrence with Alzheimer's disease proteinopathy Open
INTRODUCTION Multi‐etiology dementia necessitates in vivo markers of copathologies including misfolded ‐synuclein (syn). We measured misfolded syn aggregates (syn‐seeds) via qualitative seed amplification assays (synSAA) and examined relat…
View article: 19 (13A) Proteomic profiling of acute sport-related concussion in football players
19 (13A) Proteomic profiling of acute sport-related concussion in football players Open
View article: Targeted proteomic biomarker profiling using NULISA in a cohort enriched with risk for Alzheimer's disease and related dementias
Targeted proteomic biomarker profiling using NULISA in a cohort enriched with risk for Alzheimer's disease and related dementias Open
INTRODUCTION Targeted proteomic assays may be useful for diagnosing and staging Alzheimer's disease and related dementias (ADRD). We evaluated the performance of a 120‐marker central nervous system (CNS) NUcleic acid Linked Immuno‐Sandwich…
View article: The performance of plasma p‐tau217 in Black middle‐aged and older adults
The performance of plasma p‐tau217 in Black middle‐aged and older adults Open
INTRODUCTION Medical conditions prevalent in Black adults within the United States have been associated with plasma tau phosphorylated at threonine 217 (p‐tau217); however, insufficient p‐tau217 research has been conducted with Black adult…
View article: Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's disease
Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's disease Open
INTRODUCTION Cognitively unimpaired (CU) amyloid beta (Aβ)+ individuals with elevated plasma glial fibrillary acidic protein (GFAP) have an increased risk of Alzheimer's disease (AD)‐related progression. We tested the utility of plasma GFA…
View article: Associations between the logical memory test story recall metrics and plasma biomarkers for Alzheimer’s disease in individuals free of dementia
Associations between the logical memory test story recall metrics and plasma biomarkers for Alzheimer’s disease in individuals free of dementia Open
Objective: Blood-based biomarkers are valued for their lower cost and less invasive nature, though issues with widespread implementation and accessibility remain. Process-based scores from story recall have been shown to detect neur…
View article: Longitudinal Change in Proper Names from Logical Memory Tasks are Sensitive to Plasma pTau217 Levels
Longitudinal Change in Proper Names from Logical Memory Tasks are Sensitive to Plasma pTau217 Levels Open
Background Previous studies have found connections between recall of proper names (PN) and amyloid positivity in cognitively unimpaired (CU) adults at risk for Alzheimer’s Disease (AD; Mueller et al., 2020). Given the promising prospect of…
View article: ALZpath pTau217: Multi‐cohort performance, cross‐assay comparison, and clinical launch for the identification of Alzheimer’s Disease pathology
ALZpath pTau217: Multi‐cohort performance, cross‐assay comparison, and clinical launch for the identification of Alzheimer’s Disease pathology Open
Background Blood‐based AD biomarker tests will be essential clinical tools to provide accessible and affordable screening and monitoring for AD disease‐modifying therapeutics (DMT) as well as advancing overall clinical care. Tau phosphoryl…
View article: ALZpath pTau217: Multi‐cohort performance, cross‐assay comparison, and clinical launch for the identification of Alzheimer’s Disease pathology
ALZpath pTau217: Multi‐cohort performance, cross‐assay comparison, and clinical launch for the identification of Alzheimer’s Disease pathology Open
Background Blood‐based AD biomarker tests will be essential clinical tools to provide accessible and affordable screening and monitoring for AD disease‐modifying therapeutics (DMT) as well as advancing overall clinical care. Tau phosphoryl…
View article: Plasma pTau217, gender, and synaptic density
Plasma pTau217, gender, and synaptic density Open
Background Synaptic loss is a key feature of Alzheimer’s disease (AD) dementia. In the entorhinal cortex (ERC) and hippocampus, phosphorylated tau (pTau) colocalizes with synaptosomes, and its presence may play a role in AD‐related synapti…
View article: Plasma GFAP use for population enrichment of clinical trials in preclinical Alzheimer’s disease
Plasma GFAP use for population enrichment of clinical trials in preclinical Alzheimer’s disease Open
Background We showed that plasma GFAP (a proxy of astrocyte reactivity) abnormality is key to unleashing Aβ effects on tau phosphorylation in preclinical AD. This suggests that selecting cognitively unimpaired(CU) individuals with both hig…
View article: Seed amplification assay‐determined alpha‐synuclein associates with Alzheimer’s pathology, clinical symptoms, and cognitive change
Seed amplification assay‐determined alpha‐synuclein associates with Alzheimer’s pathology, clinical symptoms, and cognitive change Open
Background The high prevalence of mixed‐pathology dementias suggests that multi‐drug treatments may improve clinical outcomes; thus, in‐vivo biomarkers for co‐pathologies are needed. We investigated a novel assay for detecting seeds of mis…
View article: ALZpath pTau217: Alzheimer’s disease specificity in the context of multiple comorbidities and predictive capabilities for amyloid burden in combination with other blood‐based biomarkers
ALZpath pTau217: Alzheimer’s disease specificity in the context of multiple comorbidities and predictive capabilities for amyloid burden in combination with other blood‐based biomarkers Open
Background Tau phosphorylated at position 217 (pTau217) is considered to have the highest accuracy in identifying Alzheimer’s disease (AD) pathology using blood. We describe a multi‐cohort evaluation of the Simoa ALZpath pTau217 assay for …
View article: Alzheimer’s Disease Plasma Biomarker Results from across 14 Alzheimer’s Disease Research Centers
Alzheimer’s Disease Plasma Biomarker Results from across 14 Alzheimer’s Disease Research Centers Open
Background The Alzheimer’s Disease Center Fluid Biomarker (ADCFB) Initiative samples are analyzed centrally at NCRAD for AD plasma biomarkers. When combining NACC accessible data from across centers, biofluid biomarker data must be evaluat…
View article: Longitudinal Plasma pTau217 Measurements in Preclinical Alzheimer’s Disease
Longitudinal Plasma pTau217 Measurements in Preclinical Alzheimer’s Disease Open
Background Plasma pTau217 (tau phosphorylated at threonine 217) assays will expand access to screening for Alzheimer’s disease (AD). However, clinical interpretation is not well‐established, particularly during the preclinical window when …
View article: Novel fluid biomarker detects TDP‐43 loss of function in individuals at elevated risk of Alzheimer’s disease
Novel fluid biomarker detects TDP‐43 loss of function in individuals at elevated risk of Alzheimer’s disease Open
Background TDP‐43 nuclear clearance and cytoplasmic aggregation occur in an estimated 30‐60% of cases of Alzheimer’s disease (AD), but this pathology can currently only be established at autopsy. Nuclear clearance of TDP‐43 leads to inclus…
View article: Neurobiological correlates of grey matter morphometry changes in preclinical Alzheimer’s disease
Neurobiological correlates of grey matter morphometry changes in preclinical Alzheimer’s disease Open
Background The driving mechanisms of structural brain alterations in the earliest stages of Alzheimer's disease (AD) are not well understood. Previous heterogeneous findings in preclinical AD, including subtle atrophy and also increased gr…
View article: Effect of Refrigeration on Alzheimer’s Disease Biomarker Measurements in Plasma
Effect of Refrigeration on Alzheimer’s Disease Biomarker Measurements in Plasma Open
Background Mobile phlebotomy is an attractive option for the study of Alzheimer’s disease (AD) in rural and underserved populations, but logistics of collecting, and shipping these samples outside clinical settings can introduce additional…
View article: Neurobiological correlates of grey matter morphometry changes in preclinical Alzheimer's disease
Neurobiological correlates of grey matter morphometry changes in preclinical Alzheimer's disease Open
Background The driving mechanisms of structural brain alterations in the earliest stages of Alzheimer's disease (AD) are not well understood. Previous heterogeneous findings in preclinical AD, including subtle atrophy and also increased gr…
View article: Targeted Proteomic Biomarker Profiling Using NULISA in a cohort enriched with risk for Alzheimer’s Disease and Related Dementias
Targeted Proteomic Biomarker Profiling Using NULISA in a cohort enriched with risk for Alzheimer’s Disease and Related Dementias Open
Structured Abstract INTRODUCTION Targeted proteomic assays may be useful for diagnosing and staging Alzheimer’s disease and related dementias (ADRD). We evaluated the performance of a 120-marker central nervous system (CNS) NUcleic acid-Li…
View article: Visual read of [F‐18]florquinitau PET that includes and extends beyond the mesial temporal lobe is associated with increased plasma pTau217 and cognitive decline in a cohort that is enriched with risk for Alzheimer's disease
Visual read of [F‐18]florquinitau PET that includes and extends beyond the mesial temporal lobe is associated with increased plasma pTau217 and cognitive decline in a cohort that is enriched with risk for Alzheimer's disease Open
INTRODUCTION Patterns of signal from tau positron emission tomography (tau‐PET) confined to the medial temporal lobe (MTL) or extended into the neocortex may be relevant for Alzheimer's disease (AD) research if they are linked to different…
View article: Identification of late-stage tau accumulation using plasma phospho-tau217
Identification of late-stage tau accumulation using plasma phospho-tau217 Open
View article: Misfolded alpha synuclein co-occurrence with Alzheimer’s disease proteinopathy
Misfolded alpha synuclein co-occurrence with Alzheimer’s disease proteinopathy Open
INTRODUCTION Multi-etiology dementia necessitates in-vivo markers of copathologies including misfolded α -synuclein (syn). We measured misfolded syn aggregates (syn-seeds) via qualitative seed amplifcation assays (synSAA) and examined rela…
View article: CSF dynamics throughout the ventricular system using 4D flow MRI: associations to arterial pulsatility, ventricular volumes, and age
CSF dynamics throughout the ventricular system using 4D flow MRI: associations to arterial pulsatility, ventricular volumes, and age Open
View article: Longitudinal plasma phosphorylated‐tau217 and other related biomarkers in a non‐demented Alzheimer's risk‐enhanced sample
Longitudinal plasma phosphorylated‐tau217 and other related biomarkers in a non‐demented Alzheimer's risk‐enhanced sample Open
INTRODUCTION Understanding longitudinal change in key plasma biomarkers will aid in detecting presymptomatic Alzheimer's disease (AD). METHODS Serial plasma samples from 424 Wisconsin Registry for Alzheimer's Prevention participants were a…